We are pleased to share an updated compendium of clinical experience involving Low-Intensity Shock Wave Therapy (LISWT) using the MORENOVA® device. This document provides an aggregated overview of patient outcomes across several treatment settings, offering valuable insights into the clinical utility of LISWT as a regenerative treatment for erectile dysfunction (ED).
The compendium includes results from multiple clinics treating men with varying degrees of ED — often in the presence of comorbidities such as hypertension, diabetes, and post-prostatectomy complications. MORENOVA® is used to deliver focused shockwaves to the penile tissue to stimulate neovascularization and improve blood flow, offering a non-invasive, drug-free approach to treatment.
Across these clinical environments, patients underwent a standardized course of five LISWT sessions, administered over 2–5 weeks. Outcomes were assessed using validated tools such as:
- SHIM (Sexual Health Inventory for Men)
- EHS (Erection Hardness Score)
Efficacy
- Consistent improvements were reported in both SHIM and EHS scores post-treatment.
- Many patients exhibited sustained improvement at 1- and 3-month follow-ups.
- In AI-assisted analyses of qualitative feedback, approximately 70% of patients expressed positive sentiment, citing enhanced erectile function and treatment satisfaction.
Patient Profile
- Wide age range: 20–78 years
- Many patients had longstanding ED and were previously unresponsive to oral PDE5 inhibitors
- Several had vascular comorbidities, making them suitable candidates for regenerative therapy
Tolerability and Compliance
- Treatments were well-tolerated, with no reported adverse events
- High adherence to the protocol was noted, with minimal drop-out
About the MORENOVA® Device
MORENOVA® is a compact shockwave therapy system designed to deliver 1,800 focused waves per session using linear applicator technology. Developed by DIREX Group, the system is engineered for comfort, convenience, and clinical flexibility.
Its applications are particularly beneficial for patients who:
- Are not candidates for oral ED medications
- Have vascular or neurological risk factors
- Prefer a regenerative, device-based solution over pharmacological treatment
Download the full PDF >> https://direxgroup.com/wp-content/uploads/2025/06/Compendium_ED_pagenumber.pdf